Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 39531138 · doi:10.1007/s11892-024-01557-z
What was done
A systematic review and random-effects meta-analysis of 8 randomized controlled trials published between 2021 and 2023 evaluating oral nicotinamide mononucleotide (NMN) supplementation. The analysis included 342 middle-aged and older adults (49% female, primarily non-diabetic) receiving NMN doses ranging from 250 to 2000 mg/day for durations between 14 days and 12 weeks. Outcomes assessed were fasting glucose, fasting insulin, glycated hemoglobin, homeostatic model assessment for insulin resistance (HOMA-IR), and lipid profile markers.
What was found
Random-effects meta-analyses showed no statistically significant benefit of NMN on fasting glucose, fasting insulin, glycated hemoglobin, HOMA-IR, or lipid profile markers. Exact numerical effect sizes and confidence intervals were not provided in the abstract.
Why it matters
Despite claims regarding NMN and metabolic health, current randomized trial evidence does not support short-term benefits for glycemic control or lipid parameters in predominantly non-diabetic adults.
Limits
The total sample size across all 8 trials is small (342 participants), intervention durations were short (up to 12 weeks), and participants were mainly relatively healthy and non-diabetic, leaving effects on populations with established metabolic disease unknown.
Cited by
- contradicts Human clinical trials have demonstrated that sirtuin activation via NMN lowers body weight, reduces inflammation, and improves cholesterol levels.